Pharmakotherapie der bipolaren Störungen und der Manie
Abstract
Die pharmakologische Therapie der bipolaren Störung stellt im Rahmen eines bio-psychosozialen Krankheitsmodells eine Herausforderung dar. Die klinische Symptomatik kann sich in akuter Manie, Hypomanie, bipolarer Depression und Mischzuständen manifestieren. Besondere Beachtung verdient die Adhärenz, welche sich ebenso vielschichtig äussern kann, und bei welcher Komorbiditäten eine wichtige Rolle spielen. In diesem Artikel wird eine Zusammenstellung wichtiger nationaler und internationaler Therapierichtlinien zu bipolaren Störungen diskutiert und wesentliche Resultate synoptisch präsentiert mit dem Ziel, der interessierten Leserschaft einen raschen Überblick über aktuelle pharmakologische Therapiemodalitäten zu erlauben.
Pharmacotherapy of bipolar disorder is challenging. Symptomatology over the course of the disease can manifest in different ways: as acute mania, hypomania, bipolar depression and mixed states. Adherence of patients with bipolar disorder is complex, and psychiatric comorbidities play an important role. Relevant national and international guidelines are discussed in this review, and state-of-the-art recommendations are presented. A major purpose is to provide the reader with an appropriate overview of current treatment modalities.
Literatur
(2000). Diagnostic and Statistical Manual of Mental Disorders, Text Revision (4th ed.). Washington DC: American Psychiatric Association.
(2013). Diagnostic and Statistical Manual of Mental Disorders (5th ed.). Washington DC: American Psychiatric Association.
(2005). Suicide in 406 mood-disorder patients with and without long-term medication: a 40 to 44 years' follow-up. Archives of Suicide Research, 9, 279–300.
(2013). Bipolar disorders in DSM-5: strengths, problems and perspectives. International Journal of Bipolar Disorders, 1, 12.
(2013). Next steps for bipolar disorders: personalized medicine. Symposium on bipolar disorders. 21st Congress of Psychiatry, Nice, European Psychiatric Association.
(2014). Variant GADL1 and response to lithium therapy in bipolar I disorder. The New England Journal of Medicine, 370, 119–128.
(2011). Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet, 378, 1306–1315.
(2013). Duration of untreated bipolar disorder: missed opportunities on the long road to optimal treatment. Acta Psychiatrica Scandinavica, 127, 136–144.
(2012). Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry . European Archives of Psychiatry and Clinical Neurosciences, 262, Supplement 1, 1–48.
(2012). Treatment of mixed bipolar states. International Journal of Neuropsychopharmacology, 15, 1015–1026.
(2013). A systematic review of the evidence on the treatment of rapid cycling bipolar disorder. Bipolar Disorders, 15, 115–137.
(2012). The message of the survival curves: I. Composite analysis of long-term treatment studies in bipolar disorder. Neuropsychopharmacologia Hungarica, 14, 155–164.
(2009). The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. The World Journal of Biological Psychiatry, 10, 85–116.
(2010). The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2010 on the treatment of acute bipolar depression. The World Journal of Biological Psychiatry, 11, 81–109.
(2013). The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. The World Journal of Biological Psychiatry, 14, 154–219.
(2012). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. The World Journal of Biological Psychiatry, 13, 318–378.
(2011). Behandlungsempfehlungen für bipolare Störungen. Schweizerisches Medizinisches Forum, 11, 308–331.
(2011). Evaluation of drug interactions in a large sample of psychiatric inpatients: a data interface for mass analysis with clinical decision support software. Clinical Pharmacology and Therapeutics, 90, 588–596.
(2006). PSIAC – der Interaktionscomputer für die Psychiatrie. Online unter www.psiac.de.
(Hrsg.)(2013). Bipolare Störungen. Konsensus-Statement – State of the art 2013. Online unter www.oegpb.at/mm/Kons_Bipolar.pdf.
(2013). Determinants of adherence to treatment in bipolar disorder: A comprehensive review. Journal of Affective Disorders, 149, 247–252.
(2012). Association between antidepressant resistance in unipolar depression and subsequent bipolar disorder: cohort study. British Journal of Psychiatry, 200, 45–51.
(2012). Lithium toxicity profile: a systematic review and meta-analysis. Lancet, 379, 721–728.
(2013). The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. American Journal of Psychiatry, 170, 1249–1262.
(2012). S3-Leitlinie zur Diagnostik und Therapie bipolarer Störungen. Entwicklungsprozess und wesentliche Empfehlungen. Der Nervenarzt, 83, 568–586.
(2014). More pernicious course of bipolar disorder in the United States than in many European countries: Implications for policy and treatment. Journal of Affective Disorders, 160, 27–33.
(2008). Determinants of voluntary vs. involuntary admission in bipolar disorder and the impact of adherence. Results from the EMBLEM Study on acute mania of bipolar disorder. Pharmacopsychiatry, 41, 29–36.
(2011). Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. Journal of Clinical Psychiatry, 72, 156–167.
(2013). CANMAT Guidelines commentary: where does the evidence come from, and how can we use it for our patients? Bipolar Disorders, 15, 45–49.
(2014). DSM-5 criteria for bipolar disorder – what has changed? In Symposium: Mania with depressive features – bipolar disorder is bipolar again. 22nd European Congress of Psychiatry, Munich. European Psychiatric Association.
(2014). Phenomenology of manic episodes according to the presence or absence of depressive features as defined in DSM-5: Results from the IMPACT self-reported online survey. Journal of Affective Disorders, 156, 206–213.
(2013). Clinical management and burden of bipolar disorder: results from a multinational longitudinal study (WAVE-bd). International Journal of Neuropsychopharmacology, 16, 1719–1732.
(2012). The European Psychiatric Association (EPA) guidance on suicide treatment and prevention. European Psychiatry, 27, 129–141.
(2013). Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet, 382, 1575–1586.
(2013). Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disorders, 15, 1–4.
(2011). Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropsychopharmacology, 36, 375–389.